Axiom hopes it 'solved 2 major potholes' for stem cell biotechs

Axiom Biosciences' umbilical cord-derived mesenchymal stem cell therapy achieved 0% mortality in nine newborns with severe brain injury (IVH and HIE) in Phase 1, with no treatment-related serious adverse events. The company claims to have solved manufacturing control and blood-brain barrier delivery challenges that have historically delayed MSC therapies, and plans Phase 2b expansion into adult ischemic stroke. If you're selling manufacturing control, cell conditioning, or neurodelivery systems to stem cell companies, Axiom just proved the problems you solve are worth solving: two regulatory hurdles that killed Mesoblast twice now have a working solution in clinical hands. Your buyer pool just expanded from speculative to validated.